热休克蛋白90（Hsp90）的天然产物抑制剂：药物研发的潜在先导物
Natural product inhibitors of Hsp90: potential leads for drug discovery.
作者信息
Amolins M W, Blagg B S J
机构信息
Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, Kansas 66045-7563, USA.
出版信息
Mini Rev Med Chem. 2009 Feb;9(2):140-52. doi: 10.2174/138955709787316056.
Abstract
Heat shock protein 90 has emerged as a promising target for the treatment of cancer and neurodegenerative diseases. This review summarizes recent advancements towards the development of natural products as they pertain to the biological and chemical understanding of this molecular chaperone.
摘要
热休克蛋白90已成为治疗癌症和神经退行性疾病的一个有前景的靶点。本综述总结了天然产物开发方面的最新进展，这些进展与对这种分子伴侣的生物学和化学理解有关。
相似文献
1
Natural product inhibitors of Hsp90: potential leads for drug discovery.
Mini Rev Med Chem. 2009 Feb;9(2):140-52. doi: 10.2174/138955709787316056.
2
Small molecule inhibitors targeting heat shock protein 90: An updated review.
Eur J Med Chem. 2024 Sep 5;275:116562. doi: 10.1016/j.ejmech.2024.116562. Epub 2024 Jun 3.
3
Natural heat shock protein 90 inhibitors in cancer and inflammation.
Eur J Med Chem. 2020 Mar 1;189:112063. doi: 10.1016/j.ejmech.2020.112063. Epub 2020 Jan 11.
4
Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
Med Res Rev. 2016 Jan;36(1):92-118. doi: 10.1002/med.21351. Epub 2015 May 25.
5
Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
Nat Prod Rep. 2013 Oct 11;30(10):1299-323. doi: 10.1039/c3np70012g. Epub 2013 Aug 12.
6
Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors.
Med Chem. 2018;14(1):44-52. doi: 10.2174/1573406413666170623085534.
7
Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
Curr Top Med Chem. 2006;6(11):1163-71. doi: 10.2174/156802606777811979.
8
Purine-scaffold Hsp90 inhibitors.
Curr Top Med Chem. 2009;9(15):1436-46. doi: 10.2174/156802609789895737.
9
Recent update on discovery and development of Hsp90 inhibitors as senolytic agents.
Int J Biol Macromol. 2020 Oct 15;161:1086-1098. doi: 10.1016/j.ijbiomac.2020.06.115. Epub 2020 Jun 16.
10
Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies.
Comput Biol Chem. 2019 Dec;83:107113. doi: 10.1016/j.compbiolchem.2019.107113. Epub 2019 Sep 5.
引用本文的文献
1
In Vitro Release and In Vivo Study of Recombinant TGF-β and EGCG from Dual Self-Cross-Linked Alginate-Di-Aldehyde Injectable Hydrogel for the Repair of a Degenerated Intervertebral Disc in a Rat Tail.
Gels. 2025 Jul 22;11(8):565. doi: 10.3390/gels11080565.
2
Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?
Int J Mol Sci. 2024 Jun 1;25(11):6099. doi: 10.3390/ijms25116099.
3
Evaluation of the Anti-Metastatic Effect of Foeniculum Vulgare on the Protein Expression of HSP 70 & 90 in Balb/c Mice with 4t1 Model of Breast Cancer.
Asian Pac J Cancer Prev. 2023 Mar 1;24(3):833-840. doi: 10.31557/APJCP.2023.24.3.833.
4
Natural Products Targeting Hsp90 for a Concurrent Strategy in Glioblastoma and Neurodegeneration.
Metabolites. 2022 Nov 21;12(11):1153. doi: 10.3390/metabo12111153.
5
Synthesis and Biological Activity of 3-(Heteroaryl)quinolin-2(1)-ones Bis-Heterocycles as Potential Inhibitors of the Protein Folding Machinery Hsp90.
Molecules. 2022 Jan 9;27(2):412. doi: 10.3390/molecules27020412.
6
Natural compounds in the regulation of proteostatic pathways: An invincible artillery against stress, ageing, and diseases.
Acta Pharm Sin B. 2021 Oct;11(10):2995-3014. doi: 10.1016/j.apsb.2021.01.006. Epub 2021 Jan 7.
7
Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy.
Cells. 2021 Mar 17;10(3):670. doi: 10.3390/cells10030670.
8
Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence.
Front Pharmacol. 2021 Jan 18;11:592654. doi: 10.3389/fphar.2020.592654. eCollection 2020.
9
National Institute on Aging Workshop: Repurposing Drugs or Dietary Supplements for Their Senolytic or Senomorphic Effects: Considerations for Clinical Trials.
J Gerontol A Biol Sci Med Sci. 2021 May 22;76(6):1144-1152. doi: 10.1093/gerona/glab028.
10
A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.
Cold Spring Harb Perspect Biol. 2020 Apr 1;12(4):a034116. doi: 10.1101/cshperspect.a034116.
本文引用的文献
1
The exploration of macrocycles for drug discovery--an underexploited structural class.
Nat Rev Drug Discov. 2008 Jul;7(7):608-24. doi: 10.1038/nrd2590.
2
Heat shock protein 90 inhibition in lung cancer.
J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S152-9. doi: 10.1097/JTO.0b013e318174ea3a.
3
Total synthesis of the Hsp90 inhibitor geldanamycin.
Org Lett. 2008 Jun 19;10(12):2477-9. doi: 10.1021/ol800749w. Epub 2008 May 20.
4
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Leukemia. 2008 Jul;22(7):1402-9. doi: 10.1038/leu.2008.89. Epub 2008 Apr 17.
5
Recent Advances in the Study of hsp90 Structure and Mechanism of Action.
Trends Endocrinol Metab. 1998 Aug;9(6):238-43. doi: 10.1016/s1043-2760(98)00060-5.
6
Molecular characterization of macbecin as an Hsp90 inhibitor.
J Med Chem. 2008 May 8;51(9):2853-7. doi: 10.1021/jm701558c. Epub 2008 Mar 22.
7
Designed TPR modules as novel anticancer agents.
ACS Chem Biol. 2008 Mar 20;3(3):161-6. doi: 10.1021/cb700260z.
8
Proteomics of breast cancer: the quest for markers and therapeutic targets.
J Proteome Res. 2008 Apr;7(4):1403-11. doi: 10.1021/pr700870c. Epub 2008 Feb 27.
9
Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
J Org Chem. 2008 Mar 21;73(6):2130-7. doi: 10.1021/jo702191a. Epub 2008 Feb 23.
10
The Hsp90 molecular chaperone: an open and shut case for treatment.
Biochem J. 2008 Mar 15;410(3):439-53. doi: 10.1042/BJ20071640.
Zotero 插件